US Patent

US12077533 — Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides

Method of Use · Assigned to Pfizer Inc · Expires 2034-12-03 · 9y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method for treating alopecia using certain pyrrolo[2,3-d]pyrimidinyl acrylamides.

USPTO Abstract

The present invention provides a method for treating alopecia using certain pharmaceutically active pyrrolo[2,3-d]pyrimidinyl acrylamides having the structure:or a pharmaceutically acceptable salt thereof, as set forth in the Description.

Drugs covered by this patent

Litfulo (Ritlecitinib Tosylate) · Pfizer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3994`	—	Litfulo

Patent Metadata

Patent number: US12077533
Jurisdiction: US
Classification: Method of Use
Expires: 2034-12-03
Drug substance claim: No
Drug product claim: No
Assignee: Pfizer Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.